For most people, the trip from the Whitehead Institute at MIT (the Massachusetts Institute of Technology) to Harvard Medical School is a two-mile bus ride. For Richard Mulligan, who late last year became the first director of the Harvard Gene Therapy Initiative, it seems like a voyage to a new world.
It is daunting enough that Mulligan had to move from the MIT's 'research is all that counts' atmosphere to the 'it wouldn't hurt to wear a tie' corridors of Harvard Medical School and its affiliated hospitals, which are joint sponsors of the initiative. But for Mulligan, who appeared tieless for an interview at an upscale Cambridge restaurant, the move represents an even greater leap -from skeptic about gene therapy to true believer. As a founder member of the RAC -the Recombinant DNA Advisory Committee set up to screen gene therapy protocols for the US National Institutes of Health (NIH) -Mulligan became known as a nitpicking critic of what he saw as premature attempts to conduct human studies of scientifically dubious genetic therapies. He was seen as wanting to have it both ways, saying yes to basic research but no to clinical trials. In his new post, he has assumed responsibility for actually making gene therapy work in humans.
Mulligan earned his reputation by developing and testing some of the earliest and most successful vector systems for delivering genes to experimental animals. Shaped by his undergraduate years at MIT and 15 years on the faculty there, Mulligan admits he was a purist about most of the applications that poured in to the RAC. At MIT, he had been trained to critically evaluate data, without allowing any implications of the findings to bias his interpretation. By contrast, he says "some people interpreted their scientific data poorly in order to go forward in the clinic."
Some of gene therapy's early advocates were clinicians who criticized Mulligan for his hesitation. He remembers them arguing that they had patients dying and needed to move ahead despite not having all the facts. Mulligan also raised some colleagues' ire by warning that shoddy gene therapy experiments would soil the field. Now, a decade later, Mulligan's skepticism has been validated at the highest possible level. A 1995 report by an influential NIH-appointed committee slammed prior gene therapy trials as unsuccessful and "oversold," filled with experiments that suffered from weak design and non-informative outcomes. Worse yet, despite a NIH gene therapy budget of $200 million a year, the report found that there had been a "very low frequency of gene transfer" and that in more than 100 protocols, not a single patient had been definitively helped. Consequently, the report called for a return to basic laboratory science rather than longshot studies of patients.
"I could have written that report myself five years earlier," says Mulligan, who by then was on sabbatical at Somatix, a California biotechnology company he had helped to found. His stint in biotech also confirmed that there was a lot of basic research still to be done before the field would be ready for companies to kick in with the developmental phase. Mulligan's own laboratory work, which he continued even while working at the company, never strayed from a fundamental rule: "If gene therapy were banned tomorrow, would our science be of intrinsic interest?"
At the same time, even as the clinical failures piled up, Mulligan's confidence grew that someday human gene therapy would succeed -and that the field would proceed without him if he did not find a way to become active in moving the basic science discoveries into the clinic.
It would have been easy enough to stay on at Somatix. "They were beginning to work on cancer vaccines, which I had been very interested in," he recalls, ". . . and they were beginning to succeed," at least in certain systems. Despite all these enticements, Mulligan did not agree to moveand leave a position at the Whitehead that he fondly recalls as "the best job in the world" -until he became convinced that his Harvard colleagues were skeptics too. "There was long-term optimism mixed with scientific conservatism," the ideal mix. "I didn't have to cheapen my way of doing things."
In Mulligan's view, he himself and Harvard are not the only beneficiaries. The fact that Harvard is taking an active role in gene therapy will also increase the chances that gene therapy will be better sooner. Because of Harvard's conservatism, it will not repeat the mistakes of others and rush into human trials without a long-term plan for each disease it studies.
Furthermore, Harvard provides an academic, rather than a corporate setting for the work. These days, major researchers in basic science fields have so many industry affiliations that it often makes it difficult for them to work with each other. Mulligan believes Harvard offers an unusual opportunity to bring the best minds together. "It's exactly the sort of environment needed for the basic research that will drive the development of gene therapies."
For Mulligan, says hematologist Stuart Orkin of the Children's Hospital, the Harvard offer presented a very simple choice: either make gene therapy work yourself or stop criticizing it. "In other words, put up or shut up," says Orkin. "This is putting up."
Steven Dickman is a freelance science writer based in Cambridge, Massachusetts.
Gazetteer The Novartis Foundation
What is it famous for? The name isn't well-known yet. For now, it's probably best described as 'the scientific charity formerly known as The Ciba Foundation'.
Why the change of name? The Ciba parent company no longer exists. It merged with that other pharmaceuticals giant Sandoz in December 1996 to form a new company, Novartis. In response, the Foundation adopted the name of its new benefactor on 1 September 1997.
When was it founded? Robert Käppeli, managing director of the Ciba company of Basel, Switzerland, persuaded the company to form a charitable Trust in 1947, to promote international cooperation in medical, chemical and biological research. He pushed strongly for it to be located in London, partly because English was already becoming the international language of science, but also because the laws under which UK-based charities operate would ensure complete independence for the Foundation, and he insisted the two should have no commercial ties. (Also, being Swiss, he had presumably considered the fact that charities in the UK get considerable tax breaks.)
Where is the Foundation? It took a while to find a suitable site in the bomb-damaged centre of London, but Ciba restored a fine building in Portland Place, near Regent's Park, and the doors were opened in 1949. Because the neighbourhood is thick with embassy staff and private medical practitioners from nearby Harley Street, there is a prevalence of suits and flashy cars not familiar to most scientists outside the Howard Hughes Medical Institute.
What does the Foundation do? It is best known for its Symposia -held eight times a year -and in the UK for its efforts to bridge the gap between scientists and the media. It also provides a very central and affordable hotel service at Portland Place, used by those few visiting scientists in the know.
How do I get to a Symposium? You don't, unless you're already a force to be reckoned with in your field, or one of the few Foundation bursars. The emphasis is on relaxed and intimate discussion, so groups are limited to 25 invited guests. Unlike the situation at many other meetings, the 'audience' are at least as eminent as the 'speakers', and there is slightly more time set aside for discussion than for talks -so it's not simply a case of a few hurried questions before coffee. Topics must be interdisciplinary, and the aim is to select burgeoning fields that will become hot within about the next year. In an effort to reach a wider audience without sacrificing the cosy atmosphere of the meetings, the proceedings are recorded and published almost verbatim.
How does it promote science elsewhere?
The Foundation maintains a database of leading experts in science, medicine and technologythe Media Resource Servicewhich European journalists can use to contact an expert in any given field (from asteroids to BSE). It also organizes a public debate at the British Association for the Advancement of Science Annual Science Festival -this year, on cross-species organ transplantation.
How is it financed?
The Foundation has always been funded on an annual basis by a donation from the founder company -£1.3 million in 1996. So far, the donations have remained fairly consistent, being tied to the needs of the Foundation, rather than to the fortunes of the company. It remains to be seen whether anything will change apart from the name.
